Agios制药 AGIO 深 沪
已收盘 07-02 16:00:00 美东时间
37.58
+0.500
+1.35%
华盛通- 最 高37.70
- 今 开37.42
- 成交量 79.12万股
- 最 低 36.52
- 昨 收 37.08
- 总市值 22.35亿
- 52周最高 46.00
- 市盈率 静 --
- 换手率 1.33%
- 52周最低 22.24
- 委 比 -86.25%
- 总股本 5947.16万
- 历史最高 138.85
- 量 比 0.53
- 振 幅 3.18%
- 历史最低 15.77
- 每 手 1
- 风险率 5.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 甲骨文绩后分歧大！5家上调，2家下调；Navan、Hinge Health、凯西通用获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从6美元升至10美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14美元升至14.5美元
06-12 11:32
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $31
JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price target from $36 to $31.
06-11 22:25
美股大行评级 | Susquehanna上调美光目标价从600美元升至1750美元；戴尔、MongoDB、网泰信息存储、Nextpower、Okta等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从7美元升至7.5美元；Susquehanna：维持美光科技"积极"评级，目标价从600美元升至1750美元
06-01 14:11
B of A Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $40
B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $41 to $40.
05-30 02:19
Agios Pharmaceuticals Announces EU Marketing Authorization For PYRUKYND In Adults For Treatment Of Anemia
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the European Commission (EC) has
05-22 21:18
Agios Pharmaceuticals Submits Supplemental New Drug Application To FDA Seeking Accelerated Approval Of Oral Pyruvate Kinase Activator Mitapivat; To Also Present New Data On Mitapivat At 31st European Hematology Association Congress
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the submission of its supplemental New
05-12 21:35
美股大行评级 | 潜在涨幅128.69%！Immunic获HC Wainwright & Co.升目标价至22美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immunic"买入"评级，目标价从5美元升至22美元；花旗：维持ServiceNow"买入"评级，目标价从154美元升至158美元
05-01 10:49
Agios Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 financial results.
Agios Pharmaceuticals shares are trading higher after the company reported bett...
04-30 01:07
财报速睇 | Agios制药 2026财年Q1营收0.21亿美元，同比增长133.3%；归母净利润亏损0.99亿美元，同比亏损扩大11.2%
华盛资讯4月29日讯，Agios制药公布2026财年Q1业绩，公司Q1营收0.21亿美元，同比增长133.3%，归母净利润亏损0.99亿美元，同比亏损扩大11.2%。
04-29 21:32
Earnings Scheduled For April 29, 2026
Companies Reporting Before The Bell • Extreme Networks (NASDAQ:EXTR) is likely ...
04-29 19:11
